Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing
Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN Rapamycin in Microcystic Lymphatic Malformations
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Palvella Therapeutics Strengthens QTORIN Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies Ecosystem Awards
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
QIMC Defines Multiple New Hydrogen Hot Zones in Nova Scotia, Reports Stronger Preliminary DDH-26-05 Hydrogen Readings and Triples 2026 Nova Scotia Exploration Program Across a 43-km District-Scale Corridor
